Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Terns Pharmaceuticals, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/10/2023 8-K Quarterly results
10/10/2023 SC 13G/A FIL Ltd reports a 8.4% stake in TERNS PHARMACEUTICALS INC
10/04/2023 SC 13G/A Flynn James E reports a 0% stake in Terns Pharmaceuticals, Inc.
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Updates - Terns reported positive top-line data from the Phase 2a DUET trial of TERN-501 in NASH, with TERN-501 meeting all primary and secondary endpoints - TERN-701 Phase 1 clinical trial for CML on track to initiate in second half of 2023; enrollment progress from ongoing China Phase 1 clinical trial presented at 2023 ASCO Annual Meeting - TERN-601 program in obesity highlighted in preclinical data presented at ADA’s 83rd Annual Scientific Meeting; on track to initiate Phase 1 clinical trial in second half of 2023 - Cash, cash equivalents and marketable securities of $286 million expected to provide runway into 2026 FOSTER CITY, Calif., August 8, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopha..."
08/03/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Terns Pharmaceuticals Announces Leadership Transition"
07/28/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
05/15/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals, Inc. $150,000,000 SHARES of Common Stock, Par Value $0.0001 SALES AGREEMENT",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3"
05/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Quarterly results
Docs: "Terns Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Updates - Top-line data from Phase 2a DUET clinical trial of TERN-501 in NASH expected in third quarter of 2023 - TERN-701 Phase 1 trial for CML on track to initiate in the U.S. in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at the 2023 ASCO Annual Meeting - TERN-601 program in obesity on track to initiate Phase 1 clinical trial in second half of 2023 with initial proof of concept data anticipated in 2024 - Cash, cash equivalents and marketable securities of $298 million expected to provide runway into 2026 FOSTER CITY, Calif., May 15, 2023 – Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product ca..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
03/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor Conferences Completes enrollment in Phase 2a DUET clinical trial of TERN-501 as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 ongoing; on track to initiate first-in-human clinical trial in obesity in second half of 2023 Cash and cash equivalents expected to provide runway into 2026 FOSTER CITY, Calif., March 2, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule p..."
02/14/2023 SC 13G/A Venrock Healthcare Capital Partners III, L.P. reports a 7.7% stake in Terns Pharmaceuticals, Inc.
02/14/2023 SC 13G/A Fairmount Funds Management LLC reports a 9.9% stake in Terns Pharmaceuticals, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 14.9% stake in TERNS PHARMACEUTICALS INC
02/09/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc.
02/08/2023 SC 13G/A BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/01/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Terns Pharmaceuticals to Highlight 2023 Priorities and Clinical Milestones at the 41st Annual J.P. Morgan Healthcare Conference Plans to advance diverse pipeline of five disclosed programs in oncology and metabolic diseases Expects to initiate proof of concept trials in CML and obesity and to report top-line data from DUET, the first trial assessing THR-β agonist as monotherapy and in combination with FXR agonist for NASH Cash and cash equivalents, together with the $112 million from proceeds raised in December 2022, expected to provide runway into 2026 FOSTER CITY, Calif., Jan. 5, 2023 -- Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non..."
01/03/2023 SC 13G SUVRETTA CAPITAL MANAGEMENT, LLC reports a 7% stake in Terns Pharmaceuticals, Inc.
12/29/2022 SC 13G/A LAV Biosciences Fund V, L.P. reports a 6.2% stake in Terns Pharmaceuticals, Inc.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy